{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06457919",
            "orgStudyIdInfo": {
                "id": "24-103"
            },
            "organization": {
                "fullName": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "briefTitle": "A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer",
            "officialTitle": "A Phase 1b/2 Study Evaluating the Activity of Tinengotinib (TT-00420) in Combination With Androgen Receptor Signaling Inhibitors (ARSIs) in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)",
            "therapeuticArea": [
                "Oncology and Hematology"
            ],
            "study": "a-study-of-tinengotinib-tt-in-combination-with-standard-treatments-in-people-with-prostate-cancer"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-07",
            "overallStatus": "RECRUITING",
            "startDateStruct": {
                "date": "2024-06-04",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-06",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-06-05",
            "studyFirstSubmitQcDate": "2024-06-05",
            "studyFirstPostDateStruct": {
                "date": "2024-06-13",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-07-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-07-30",
                "type": "ESTIMATED"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Memorial Sloan Kettering Cancer Center",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "TransThera Sciences",
                    "class": "UNKNOWN"
                }
            ]
        },
        "oversightModule": {
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people with metastatic castration-resistant prostate cancer (mCRPC)."
        },
        "conditionsModule": {
            "conditions": [
                "Prostate Cancer"
            ],
            "keywords": [
                "Tinengotinib (TT-00420)",
                "Androgen Receptor Signaling Inhibitors (ARSIs)",
                "TIP Study: Tinengotinib In Prostate Cancer",
                "Prostate Cancer Clinical Trials Consortium, LLC (PCCTC)",
                "24-103"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "In the Phase 1b portion of the study, participants will be enrolled sequentially in cohorts of 3 for each studied combination. The recommended Phase II dose (RP2D) of each combination will be estimated separately based on the de-escalation rules.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 50,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Tinengotinib with abiraterone acetate/prednisone",
                    "type": "EXPERIMENTAL",
                    "description": "Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily will be administered unless dose de-escalation is required in Phase 1b. Participants will receive tinengotinib in combination with abiraterone acetate 1000 mg PO QD in combination with prednisone 5 mg PO once or twice daily (QD or BID) or enzalutamide 160 mg PO QD.",
                    "interventionNames": [
                        "Drug: Tinengotinib",
                        "Drug: abiraterone acetate",
                        "Drug: Prednisone or Enzalutamide"
                    ]
                },
                {
                    "label": "Phase 1b dose of tinengotinib (RP2D) with abiraterone acetate/prednisone or enzalutamide",
                    "type": "EXPERIMENTAL",
                    "description": "Phase 1b dose of tinengotinib recommended Phase II dose (RP2D) with abiraterone acetate/prednisone or enzalutamide",
                    "interventionNames": [
                        "Drug: abiraterone acetate",
                        "Drug: Prednisone or Enzalutamide",
                        "Drug: Tinengotinib"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Tinengotinib",
                    "description": "Tinengotinib will be administered daily for 28-day cycles. A flat dose of 10 mg PO once daily.",
                    "armGroupLabels": [
                        "Tinengotinib with abiraterone acetate/prednisone"
                    ],
                    "otherNames": [
                        "TT-00420"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "abiraterone acetate",
                    "description": "Abiraterone acetate 1000 mg PO QD",
                    "armGroupLabels": [
                        "Phase 1b dose of tinengotinib (RP2D) with abiraterone acetate/prednisone or enzalutamide",
                        "Tinengotinib with abiraterone acetate/prednisone"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Prednisone or Enzalutamide",
                    "description": "Prednisone 5 mg PO once or twice daily (QD or BID) or enzalutamide 160 mg PO QD",
                    "armGroupLabels": [
                        "Phase 1b dose of tinengotinib (RP2D) with abiraterone acetate/prednisone or enzalutamide",
                        "Tinengotinib with abiraterone acetate/prednisone"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Tinengotinib",
                    "description": "The recommended phase 2 dose (RP2D).",
                    "armGroupLabels": [
                        "Phase 1b dose of tinengotinib (RP2D) with abiraterone acetate/prednisone or enzalutamide"
                    ],
                    "otherNames": [
                        "TT-00420"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "RP2D",
                    "description": "Evaluate DLT occurrence to confirm safety and RP2D",
                    "timeFrame": "From the start of study treatment through the DLT window (28 days)"
                },
                {
                    "measure": "Objective Response Rate (ORR)",
                    "description": "by local investigator's assessment per PCWG3-modified RECIST v1.1 in participants with baseline measurable disease OR rate of PSA decline of \u2265 50% from baseline in patients with a baseline PSA of 2.0 ng/mL or above",
                    "timeFrame": "up to 6months"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Time to Radiographic Response (phase II)",
                    "description": "Time to radiographic response by local investigator's assessment per PCWG3-modified RECIST v1.1 in participants with baseline measurable disease (CR) or Partial Response (PR) per Prostate Cancer Clinical Trials Working Group 3 (PCWG3)-modified RECIST v1.1 in patients with baseline measurable disease",
                    "timeFrame": "From start of study treatment until 6 months post study treatment start"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Participants \u2265 18 years old, with signed informed consent\n* Histologically confirmed carcinoma of the prostate (neuroendocrine differentiation is allowed, but pure small cell carcinoma is not permitted)\n* Metastatic disease documented by at least 2 bone lesions on whole body radionuclide bone scan, or soft tissue disease documented by computed tomography (CT) scan/magnetic resonance imaging (MRI). Note: Metastatic disease seen only on PET imaging does not qualify.\n* Current ongoing therapy and observed tolerance with full standard dose of abiraterone acetate (1000 mg QD) or enzalutamide (160 mg QD) at the time of study entry, started at least 90 days before consent. An interruption of dosing of a maximum of 30 days is permitted prior to resuming the agent. Please note: Patients who are on a reduced dose or are intolerant of abiraterone acetate or enzalutamide will not be eligible for study participation.\n* Progressive disease on enzalutamide or abiraterone acetate documented by PCWG3 criteria for study entry. Progressive disease is defined as at least one of the following:\n\n  1. PSA progression defined as a minimum of 2 rising PSA levels with a minimum of a 1-week interval between each determination, reaching a minimum PSA value of 1.0 ng/mL.\n  2. Nodal or visceral progression as defined by PCWG3-modified RECIST 1.1\n  3. Appearance of 2 or more new lesions on a bone scan\n* At least one of the following at study entry:\n\n  1. RECIST 1.1 measurable disease at baseline; i.e., soft tissue tumor lesions or pathologically enlarged lymph nodes that can be accurately measured in at least one dimension OR\n  2. a PSA of 2.0 ng/mL or above\n* Participants must be medically or surgically castrated with ongoing androgen deprivation therapy (ADT) for \u226590 days or have documented history of bilateral orchiectomy.\n* ECOG 0 - 2\n* Adequate organ function confirmed at screening, as evidenced by:\n\n  * Absolute neutrophil count \u2265 1.5 \u00d7 10\\^9 /L\n  * Hemoglobin \u2265 9 g/dL\n  * Platelets \u2265 75 \u00d7 10\\^9 /L\n  * Aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) \u2264 2.5 \u00d7 upper limit of normal (ULN) or \u2264 5.0 \u00d7 ULN if liver metastases are present\n  * Total bilirubin \u2264 1.5 \u00d7 ULN; or \\< 2.5 \u00d7 ULN if Gilbert syndrome or disease involving liver\n  * Creatinine clearance \\>30 mL/min (Cockcroft-Gault formula)\n  * Adequate blood coagulation function as evidence by an international normalized ratio (INR) \u2264 1.5 unless participant is on anticoagulants\n* Tumor biopsy during screening is required if safe and feasible.\n\nExclusion Criteria:\n\n* The presence of any of the following criteria excludes a patient from participating in the study:\n* Pure small cell carcinoma\n* Previous exposure to multi-TKI therapies.\n* Uncontrolled hypertension (persistent systolic blood pressure \u2265 140 mm Hg and/or diastolic blood pressure \u2265 90 mm Hg) or known coronary artery disease with angina. Patients with known hypertension must be on antihypertensive medication with BPs generally \\<140/90 to be eligible.\n* History of congestive heart failure of Class II-IV New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment (except atrial fibrillation, paroxysmal supraventricular tachycardia), history of myocardial infarction within 6 months of study entry, or QT interval corrected by the Fridericia correction formula (QTcF) \\>480 msec at screening.\n* Any prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessments.\n* Symptomatic and/or untreated CNS metastases.\n* Pre-existing duodenal stent or any gastrointestinal disorder or defect which would interfere with absorption of study medication, as determined by the Investigator.\n* Requirement for systemic therapy with either corticosteroids (\\>10 mg daily prednisone equivalents) or immunosuppressive medications within 14 days before study treatment start.\n* Other anticancer therapies within 3 weeks of study treatment start, or within 5 half-lives of study treatment start for non-cytotoxic oral agents, whichever is shorter; with the exception of androgen deprivation therapy, enzalutamide, or abiraterone acetate which should be continued through study treatment.\n* Palliative radiation within 2 weeks of study treatment start.",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "genderDescription": "Prostate cancer",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Wassim Abida, MD, PhD",
                    "role": "CONTACT",
                    "phone": "646-442-4633",
                    "email": "abidam@mskcc.org"
                },
                {
                    "name": "Samir Zaidi, MD,PhD",
                    "role": "CONTACT",
                    "phone": "646-888-3698"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Wassim Abida, MD, PhD",
                    "affiliation": "Memorial Sloan Kettering Cancer Center",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Basking Ridge",
                    "state": "New Jersey",
                    "zip": "07920",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Wassim Abida, MD, PhD",
                            "role": "CONTACT",
                            "phone": "646-442-4633"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.70621,
                        "lon": -74.54932
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Monmouth (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Middletown",
                    "state": "New Jersey",
                    "zip": "07748",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Wassim Abida, MD, PhD",
                            "role": "CONTACT",
                            "phone": "646-442-4633"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.39652,
                        "lon": -74.09211
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Bergen (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Montvale",
                    "state": "New Jersey",
                    "zip": "07645",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Wassim Abida, MD, PhD",
                            "role": "CONTACT",
                            "phone": "646-442-4633"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.04676,
                        "lon": -74.02292
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Commack",
                    "state": "New York",
                    "zip": "11725",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Wassim Abida, MD, PhD",
                            "role": "CONTACT",
                            "phone": "646-442-4633"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.84288,
                        "lon": -73.29289
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Westchester (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Harrison",
                    "state": "New York",
                    "zip": "10604",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Wassim Abida, MD, PhD",
                            "role": "CONTACT",
                            "phone": "646-442-4633"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.96899,
                        "lon": -73.71263
                    }
                },
                {
                    "facility": "Columbia University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Mark Stein, MD",
                            "role": "CONTACT",
                            "phone": "212-305-5098"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Cancer Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10065",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Wassim Abida, MD, PhD",
                            "role": "CONTACT",
                            "phone": "646-442-4633"
                        },
                        {
                            "name": "Samir Zaidi, MD, PhD",
                            "role": "CONTACT",
                            "phone": "646-888-3698"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Memorial Sloan Kettering Nassau (Limited Protocol Activities)",
                    "status": "RECRUITING",
                    "city": "Uniondale",
                    "state": "New York",
                    "zip": "11553",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Wassim Abida, MD, PhD",
                            "role": "CONTACT",
                            "phone": "646-442-4633"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.70038,
                        "lon": -73.59291
                    }
                },
                {
                    "facility": "Duke University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Durham",
                    "state": "North Carolina",
                    "zip": "27710",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Hannah Dzimitrowicz McManus, MD",
                            "role": "CONTACT",
                            "phone": "919-668-6688"
                        }
                    ],
                    "geoPoint": {
                        "lat": 35.99403,
                        "lon": -78.89862
                    }
                },
                {
                    "facility": "Oregon Health & Science University",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Portland",
                    "state": "Oregon",
                    "zip": "97239",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Alexandra Sokolova, MD",
                            "role": "CONTACT",
                            "phone": "503-346-1500"
                        }
                    ],
                    "geoPoint": {
                        "lat": 45.52345,
                        "lon": -122.67621
                    }
                },
                {
                    "facility": "Thomas Jefferson University Hospital",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Philadelphia",
                    "state": "Pennsylvania",
                    "zip": "19107",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Raghava Levaka, MD",
                            "role": "CONTACT",
                            "phone": "215-890-3030"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.95233,
                        "lon": -75.16379
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Memorial Sloan Kettering Cancer Center",
                    "url": "http://www.mskcc.org/mskcc/html/44.cfm"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org."
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011471",
                    "term": "Prostatic Neoplasms"
                }
            ],
            "ancestors": [
                {
                    "id": "D000005834",
                    "term": "Genital Neoplasms, Male"
                },
                {
                    "id": "D000014565",
                    "term": "Urogenital Neoplasms"
                },
                {
                    "id": "D000009371",
                    "term": "Neoplasms by Site"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000005832",
                    "term": "Genital Diseases, Male"
                },
                {
                    "id": "D000091662",
                    "term": "Genital Diseases"
                },
                {
                    "id": "D000091642",
                    "term": "Urogenital Diseases"
                },
                {
                    "id": "D000011469",
                    "term": "Prostatic Diseases"
                },
                {
                    "id": "D000052801",
                    "term": "Male Urogenital Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14335",
                    "name": "Prostatic Neoplasms",
                    "asFound": "Prostate Cancer",
                    "relevance": "HIGH"
                },
                {
                    "id": "M8946",
                    "name": "Genital Neoplasms, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M17315",
                    "name": "Urogenital Neoplasms",
                    "relevance": "LOW"
                },
                {
                    "id": "M2876",
                    "name": "Genital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M8944",
                    "name": "Genital Diseases, Male",
                    "relevance": "LOW"
                },
                {
                    "id": "M2875",
                    "name": "Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M14333",
                    "name": "Prostatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M27095",
                    "name": "Male Urogenital Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "T3215",
                    "name": "Kennedy Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BXS",
                    "name": "Urinary Tract, Sexual Organs, and Pregnancy Conditions"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000011241",
                    "term": "Prednisone"
                },
                {
                    "id": "D000069501",
                    "term": "Abiraterone Acetate"
                }
            ],
            "ancestors": [
                {
                    "id": "D000000893",
                    "term": "Anti-Inflammatory Agents"
                },
                {
                    "id": "D000005938",
                    "term": "Glucocorticoids"
                },
                {
                    "id": "D000006728",
                    "term": "Hormones"
                },
                {
                    "id": "D000006730",
                    "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"
                },
                {
                    "id": "D000045505",
                    "term": "Physiological Effects of Drugs"
                },
                {
                    "id": "D000018931",
                    "term": "Antineoplastic Agents, Hormonal"
                },
                {
                    "id": "D000000970",
                    "term": "Antineoplastic Agents"
                },
                {
                    "id": "D000065088",
                    "term": "Steroid Synthesis Inhibitors"
                },
                {
                    "id": "D000004791",
                    "term": "Enzyme Inhibitors"
                },
                {
                    "id": "D000045504",
                    "term": "Molecular Mechanisms of Pharmacological Action"
                },
                {
                    "id": "D000006727",
                    "term": "Hormone Antagonists"
                },
                {
                    "id": "D000065607",
                    "term": "Cytochrome P-450 Enzyme Inhibitors"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M14121",
                    "name": "Prednisone",
                    "asFound": "Prospective",
                    "relevance": "HIGH"
                },
                {
                    "id": "M451",
                    "name": "Abiraterone Acetate",
                    "asFound": "Unilateral",
                    "relevance": "HIGH"
                },
                {
                    "id": "M4059",
                    "name": "Androgens",
                    "relevance": "LOW"
                },
                {
                    "id": "M4217",
                    "name": "Anti-Inflammatory Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M9047",
                    "name": "Glucocorticoids",
                    "relevance": "LOW"
                },
                {
                    "id": "M9789",
                    "name": "Hormones",
                    "relevance": "LOW"
                },
                {
                    "id": "M9788",
                    "name": "Hormone Antagonists",
                    "relevance": "LOW"
                },
                {
                    "id": "M20966",
                    "name": "Antineoplastic Agents, Hormonal",
                    "relevance": "LOW"
                },
                {
                    "id": "M7951",
                    "name": "Enzyme Inhibitors",
                    "relevance": "LOW"
                },
                {
                    "id": "M30537",
                    "name": "Cytochrome P-450 Enzyme Inhibitors",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Infl",
                    "name": "Anti-Inflammatory Agents"
                },
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}